Organization (Other)
Multitude Therapeutics Inc.
ClinicalTrials.gov lists Multitude Therapeutics Inc. as lead sponsor of 10 trials. It has 21 active development programs and 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
17 sections measured, none recorded
This page covers Multitude Therapeutics Inc.: 10 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (12)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Lung Neoplasms | 2 |
| Adenocarcinoma of Lung | 1 |
| Breast Neoplasms | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Carcinoma, Ovarian Epithelial | 1 |
Showing 5 of 12 disease areas.
Trials by start year as sponsor or collaborator (3)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2024 | 4 |
| 2023 | 3 |
No forecast is made for this organization: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 28 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; 2 of 7 predicted trials reach the 36-month horizon. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
Active development programs (21)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab) | Lung Neoplasms | Phase 2/3 | 1 |
| AMT-116 | Lung Neoplasms | Phase 2/3 | 1 |
| AMT-116 | Carcinoma, Non-Small-Cell Lung | Phase 2/3 | 1 |
| Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab) | Carcinoma, Non-Small-Cell Lung | Phase 2/3 | 1 |
| AMT-676 | Colorectal Neoplasms | Phase 2 | 1 |
Showing 5 of 21 active programs.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| OXALIPLATIN | 1 |
| BEVACIZUMAB | 1 |
| Irinotecan | 1 |
| CETUXIMAB | 1 |
| Calcium Leucovorin | 1 |
Showing 5 of 6 approved assets.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1 | 1 | 2025-12-16 |
Latest dated events (11)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-29 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-12-16 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2024-06-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 11 events.
Biomarker capability evidence (48)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALK | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial sponsor | Named in trial inclusion criteria |
| CSF2 | Trial sponsor | Named in trial inclusion criteria |
| CSF3 | Trial sponsor | Named in trial inclusion criteria |
| EGFR | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 48 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sponsor delivery record, journals published in, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.